Parallel-group 8-week study on chlorthalidone effects in hypertensives with low kidney function

Hypertension

Volumn 63, Issue 4, 2014, Pages 692-697

  Cirillo, Massimo ^a,b   Marcarelli, Fabiana ^b   Mele, Alessandra A ^b   Romano, Massimo ^b   Lombardi, Cinzia ^c   Bilancio, Giancarlo ^a,b  

^a UNIVERSITY OF SALERNO   (Italy)

^b University Hospital   (Italy)

^c University of Benevento   (Italy)

Author keywords

chlorthalidone; clinical trial; creatinine; glomerular filtration rate; hypertension; kidney

Indexed keywords

ANTIHYPERTENSIVE AGENT; CALCIUM; CHLORTALIDONE; CREATININE; POTASSIUM; SODIUM; URIC ACID;

ADULT; AGED; ANTIHYPERTENSIVE THERAPY; ARTICLE; CALCIUM BLOOD LEVEL; COMORBIDITY; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DIABETIC NEPHROPATHY; DIASTOLIC BLOOD PRESSURE; DISEASE SEVERITY; DRUG EFFECT; DRUG WITHDRAWAL; ESSENTIAL HYPERTENSION; ESTIMATED GLOMERULAR FILTRATION RATE; FEMALE; GLOMERULOPATHY; GLOMERULUS FILTRATION RATE; HUMAN; HYPERTENSION; HYPOTENSION; INCIDENCE; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NEPHRECTOMY; ORTHOSTATIC HYPOTENSION; PATIENT SELECTION; POTASSIUM BLOOD LEVEL; PREMEDICATION; PRIORITY JOURNAL; PROSPECTIVE STUDY; PYELONEPHRITIS; SINGLE BLIND PROCEDURE; SODIUM BLOOD LEVEL; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; TREATMENT OUTCOME; URIC ACID BLOOD LEVEL;

CHLORTHALIDONE; CLINICAL TRIAL; CREATININE; GLOMERULAR FILTRATION RATE; HYPERTENSION; KIDNEY;

ADULT; AGED; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CHLORTHALIDONE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; HYPERTENSION; KIDNEY; MALE; MIDDLE AGED; POTASSIUM; PROSPECTIVE STUDIES; SINGLE-BLIND METHOD; TREATMENT OUTCOME; URIC ACID;

EID: 84897056085     PISSN: 0194911X     EISSN: 15244563     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.113.02793     Document Type: Article

References (40)

1. Mahmoodi BK, Matsushita K, Woodward M, Blankestijn PJ, Cirillo M, Ohkubo T, Rossing P, Sarnak MJ, Stengel B, Yamagishi K, Yamashita K, Zhang L, Coresh J, de Jong PE, Astor BC; Chronic Kidney Disease Prognosis Consortium. Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without hypertension: a meta-analysis. Lancet. 2012;380:1649-1661.
2. Nitsch D, Grams M, Sang Y, Black C, Cirillo M, Djurdjev O, Iseki K, Jassal SK, Kimm H, Kronenberg F, Oien CM, Levey AS, Levin A, Woodward M, Hemmelgarn BR; Chronic Kidney Disease Prognosis Consortium. Associations of estimated glomerular fltration rate and albuminuria with mortality and renal failure by sex: a meta-analysis. BMJ. 2013;346:f324.
3. Kidney Disease: Improving Global Outcomes (KDIGO) Blood Pressure Work Group. KDIGO Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease. Kidney Inter. Suppl. 2012;2:337-414.
4. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, Jones DW, Materson BJ, Oparil S, Wright JT Jr, Roccella EJ; National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National High Blood Pressure Education Program Coordinating Committee. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA. 2003;289:2560-2572.
5. Guidelines Committee. 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003;21:1011-1053.
6. Ernst ME, Moser M. Use of diuretics in patients with hypertension. N Engl J Med. 2009;361:2153-2164.
7. Carter BL, Ernst ME, Cohen JD. Hydrochlorothiazide versus chlortha-lidone: evidence supporting their interchangeability. Hypertension. 2004;43:4-9.
8. Khosla N, Chua DY, Elliott WJ, Bakris GL. Are chlorthalidone and hydro-chlorothiazide equivalent blood-pressure-lowering medications? J Clin Hypertens (Greenwich). 2005;7:354-356.
9. Ernst ME, Carter BL, Goerdt CJ, Steffensmeier JJ, Phillips BB, Zimmerman MB, Bergus GR. Comparative antihypertensive effects of hydrochlorothiazide and chlorthalidone on ambulatory and offce blood pressure. Hypertension. 2006;47:352-358.
10. Kaplan NM. The choice of thiazide diuretics: why chlorthalidone may replace hydrochlorothiazide. Hypertension. 2009;54:951-953.
11. Jamerson KA, Bakris GL, Wun CC, Dahlöf B, Lefkowitz M, Manfreda S, Pitt B, Velazquez EJ, Weber MA. Rationale and design of the avoiding cardiovascular events through combination therapy in patients living with systolic hypertension (ACCOMPLISH) trial: the frst randomized controlled trial to compare the clinical outcome effects of frst-line combination therapies in hypertension. Am J Hypertens. 2004;17:793-801.
12. Jamerson K, Weber MA, Bakris GL, Dahlöf B, Pitt B, Shi V, Hester A, Gupte J, Gatlin M, Velazquez EJ; ACCOMPLISH Trial Investigators. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med. 2008;359:2417-2428.
13. Bakris GL, Sarafdis PA, Weir MR, Dahlöf B, Pitt B, Jamerson K, Velazquez EJ, Staikos-Byrne L, Kelly RY, Shi V, Chiang YT, Weber MA; ACCOMPLISH Trial Investigators. Renal outcomes with different fxed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecifed secondary analysis of a randomised controlled trial. Lancet. 2010;375:1173-1181.
14. Cushman WC, Ford CE, Cutler JA, et al. Success and predictors of blood pressure control in diverse North American settings: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). J Clin Hypertens. 2002;4:393-404.
15. Rahman M, Pressel S, Davis BR, et al. Renal outcomes in high-risk hypertensive patients treated with an angiotensin-converting enzyme inhibitor or a calcium channel blocker vs a diuretic: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Arch Intern Med. 2005;165:936-946.
16. Rahman M, Pressel S, Davis BR, Nwachuku C, et al. Cardiovascular outcomes in high-risk hypertensive patients stratifed by baseline glomerular fltration rate. Ann Intern Med. 2006;144:172-180.
17. Wollam GL, Tarazi RC, Bravo EL, Dustan HP. Diuretic potency of combined hydrochlorothiazide and furosemide therapy in patients with azote-mia. Am J Med. 1982;72:929-938.
18. Knauf H, Mutschler E. Diuretic effectiveness of hydrochlorothia-zide and furosemide alone and in combination in chronic renal failure. J Cardiovasc Pharmacol. 1995;26:394-400.
19. Dussol B, Moussi-Frances J, Morange S, Somma-Delpero C, Mundler O, Berland Y. A randomized trial of furosemide vs hydrochlorothiazide in patients with chronic renal failure and hypertension. Nephrol Dial Transplant. 2005;20:349-353.
20. Agarwal R, Sinha AD. Thiazide diuretics in advanced chronic kidney disease. J Am Soc Hypertens. 2012;6:299-308.
21. Sica D, Bakris GL, White WB, Weber MA, Cushman WC, Huang P, Roberts A, Kupfer S. Blood pressure-lowering effcacy of the fxed-dose combination of azilsartan medoxomil and chlorthalidone: a factorial study. J Clin Hypertens (Greenwich). 2012;14:284-292.
22. Levey AS, Coresh J, Balk E, Kausz AT, Levin A, Steffes MW, Hogg RJ, Perrone RD, Lau J, Eknoyan G; National Kidney Foundation. National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classifcation, and stratifcation. Ann Intern Med. 2003;139:137-147.
23. Levey AS, Eckardt KU, Tsukamoto Y, Levin A, Coresh J, Rossert J, De Zeeuw D, Hostetter TH, Lameire N, Eknoyan G. Defnition and classifca-tion of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 2005;67:2089-2100.
24. Stevens LA, Coresh J, Greene T, Levey AS. Assessing kidney function-measured and estimated glomerular fltration rate. N Engl J Med. 2006;354:2473-2483.
25. Myers GL, Miller WG, Coresh J, Fleming J, Greenberg N, Greene T, Hostetter T, Levey AS, Panteghini M, Welch M, Eckfeldt JH; National Kidney Disease Education Program Laboratory Working Group. Recommendations for improving serum creatinine measurement: a report from the Laboratory Working Group of the National Kidney Disease Education Program. Clin Chem. 2006;52:5-18.
26. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, Kusek JW, Eggers P, Van Lente F, Greene T, Coresh J; CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration). A new equation to estimate glomerular fltration rate. Ann Intern Med. 2009;150:604-612.
27. Cirillo M, Lombardi C, Luciano MG, Bilancio G, Anastasio P, De Santo NG. Estimation of GFR: a comparison of new and established equations. Am J Kidney Dis. 2010;56:802-804.
28. Cirillo M, Laurenzi M, Mancini M, Zanchetti A, De Santo NG. Low muscular mass and overestimation of microalbuminuria by urinary albumin/creatinine ratio. Hypertension. 2006;47:56-61.
29. Ashby JP, Wright DJ, Rinsler MG. The adjusted serum calcium concept-a reappraisal. Ann Clin Biochem. 1986;23 (Pt 5):533-537.
30. Bellomo R, Ronco C, Kellum JA, Mehta RL, Palevsky P; Acute Dialysis Quality Initiative Workgroup. Acute renal failure-defnition, outcome measures, animal models, fuid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Crit Care. 2004;8:R204-R212.
31. Julious SA. Sample sizes for clinical trials with normal data. Stat Med. 2004;23:1921-1986.
32. Chow KM, Kwan BC, Szeto CC. Clinical studies of thiazide-induced hyponatremia. J Natl Med Assoc. 2004;96:1305-1308.
33. Leung AA, Wright A, Pazo V, Karson A, Bates DW. Risk of thiazide-induced hyponatremia in patients with hypertension. Am J Med. 2011;124:1064-1072.
34. Villalon-Gomez JM. ACP Journal Club. Thiazides increased hyponatre-mia, but not hospitalizations, in patients with hypertension. Ann Intern Med. 2012, 156:JC4-11.
35. Duncan LE, Liddle GW, Bartter FC, Buck K. The effect of changes in body sodium on extracellular fuid volume and aldosterone and sodium excretion by normal and edematous men. J Clin Invest. 1956;35:1299-1305.
36. Bellomo R, Prowle JR, Echeverri JE. Diuretic therapy in fuid-overloaded and heart failure patients. Contrib Nephrol. 2010;164:153-163.
37. Klahr S, Levey AS, Beck GJ, Caggiula AW, Hunsicker L, Kusek JW, Striker G. The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. Modifcation of Diet in Renal Disease Study Group. N Engl J Med. 1994;330:877-884.
38. Apperloo AJ, de Zeeuw D, de Jong PE. A short-term antihypertensive treatment-induced fall in glomerular fltration rate predicts long-term stability of renal function. Kidney Int. 1997;51:793-797.
39. Holtkamp FA, de Zeeuw D, Thomas MC, Cooper ME, de Graeff PA, Hillege HJ, Parving HH, Brenner BM, Shahinfar S, Lambers Heerspink HJ. An acute fall in estimated glomerular fltration rate during treatment with losartan predicts a slower decrease in long-term renal function. Kidney Int. 2011;80:282-287.
40. Cirillo M, Laurenzi M, Mancini M, Zanchetti A, Lombardi C, De Santo NG. Low glomerular fltration in the population: prevalence, associated disorders, and awareness. Kidney Int. 2006;70:800-806.